PanOptica: PanOptica to Present Positive Topical AntiVEGF Eye Drop Data at OISAAO

PanOptica Inc. a private biopharmaceutical company focused on developing innovative ophthalmology therapies today announced that Paul G. Chaney president and chief executive officer will present topline data from the companys Phase 12 clinical trial of PAN...